Sigachi Industries has received a disclosure from its promoter RPS Industries Private Limited regarding the creation of a new encumbrance on equity shares. On 02.02.2026, RPS Industries submitted disclosures under Regulation 31(2) and 31(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for the creation of pledge on 25,00,000 equity shares.

New Pledge Creation Details

The disclosure reveals that RPS Industries Private Limited has pledged 25,00,000 shares representing 0.65% of Sigachi Industries' total share capital in favor of Cholamandalam Investment and Finance Ltd on 29.01.2026.

Updated Shareholding Position

Following the new pledge creation, RPS Industries Private Limited's shareholding structure in Sigachi Industries has been updated:

Regulatory Compliance

The disclosure was submitted to both BSE Limited and National Stock Exchange of India Limited on 02.02.2026. RPS Industries Private Limited, through Director Swati Sinha (DIN: 08097594), digitally signed and submitted the required documentation maintaining compliance with SEBI regulations. The new pledge represents an increase in the encumbered shareholding of the promoter entity, raising the pledged portion from 9.51% to 10.16% of Sigachi Industries' total share capital while maintaining overall shareholding of 14.74%.

Sigachi Industries has achieved a significant research and development milestone in the field of cystic fibrosis Active Pharmaceutical Ingredients (APIs). This breakthrough represents a major advancement in the company's pharmaceutical development capabilities and positions it strategically in the specialized therapeutic market.

R&D Milestone Achievement

The company has successfully reached an important R&D goal specifically related to cystic fibrosis APIs. This achievement demonstrates Sigachi Industries' commitment to developing specialized pharmaceutical ingredients for rare and complex medical conditions. Cystic fibrosis APIs represent a niche but valuable segment within the pharmaceutical industry, requiring specialized expertise and advanced manufacturing capabilities.

Revenue Projections

The successful completion of this R&D milestone is expected to translate into substantial revenue generation for the company. The following table outlines the anticipated financial impact:

Strategic Implications

This R&D achievement positions Sigachi Industries to enter a specialized pharmaceutical market segment. The development of cystic fibrosis APIs represents the company's expansion into complex therapeutic areas, potentially enhancing its product portfolio and market positioning. The expected revenue generation starting from Q4 of FY 2026-27 indicates a clear commercialization timeline for this research breakthrough.

The milestone reflects the company's investment in research and development capabilities, particularly in addressing rare disease treatments. This achievement could establish Sigachi Industries as a key player in the specialized API manufacturing sector for cystic fibrosis therapeutics.